Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

From novel targets to potential therapies: development of antisense oligonucleotides for progressive supranuclear palsy
Min, Yuhao , Bergman, Jeremiah, Tan, Jianna, Wang, Xue, Sotelo, Katie D., Reddy, Joseph S. , Quicksall, Zachary , Nguyen, Thuy T., Mitchell, Adriana O., Kawatani, Keiji , Selecky, Grace A., Reeves, Cristian A Lasagna, Crary, John F. , Kanekiyo, Takahisa , Allen, Mariet , Ertekin‐Taner, Nilüfer, Wang, Xue, Sotelo, Katie D., Nguyen, Thuy T. , Dickson, Dennis W. , Whitney, Kristen R. , Martínez, Pablo , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S5 | Pages: No page available

10.1002/alz70859_100315 Get It

Abstract Background Progressive supranuclear palsy (PSP) is a devastating neurodegenerative disorder with rapid progression to death. Multiple efforts to develop a disease‐modifying therapy for PSP have yet to succeed. We previously reported the discovery of three potential therapeutic targets for PSP. These three genes, DDR2, KANK2, and STOM, are consistently upregulated in the brains of PSP patients and mouse models of tauopathy. Reducing their expression in a drosophila model significantly rescued the tau‐induced eye degeneration and tau seeding activity. To translate these targets into the clinic, we are developing antisense oligonucleotides (ASO) as potential therapies. Method We screened candidate ASOs in neuroglioma cell line H4. ASO hits were validated for their potency and safety. We also used iPSC‐derived neurons from PSP patients to test the potency and potential toxicity of our ASOs. To investigate target engagement, therapeutic efficacy and preliminary pharmacodynamic properties, we treated iPSC‐derived midbrain organoids with the ASO leads. Lastly, we will assess the off‐target effects of the ASOs by investigating the levels of mRNA transcripts that share similar sequences as our targets using RNAseq. Result Our in vitro screening identified ASO leads that significantly reduce the target gene expressions at mRNA and protein levels in a dose‐dependent manner. The ASO hits also exhibit low cellular toxicity in the H4 cell line. Upon treating iPSC neurons with ASO hits, we were able to validate the dose‐dependent reduction of target mRNAs. Cell viability analysis indicated low toxicity, suggesting that these ASOs are potent and safe. In midbrain organoid model, DDR2‐targeting ASO showed time‐dependent target engagement and were prioritized for further development. Conclusion We developed candidate therapeutics for PSP using ASOs that silence novel therapeutic targets discovered in our systems based cross‐species screening. We showed that our ASOs have low toxicity and confirmed target engagement at both mRNA and protein levels in vitro. The results suggest a favorable preclinical profile of our ASO leads that warrants additional investigations. Importantly, PSP shares congruent pathophysiological changes with other tauopathies, such as Alzheimer’s disease. These common perturbed pathways indicate that our ASOs can be potentially repurposed for multiple neurodegenerative tauopathies.
Cell type‐specific gene expression changes are associated with cerebral amyloid angiopathy and blood‐brain barrier integrity in Alzheimer's disease
Tsai, Wei, İş, Özkan , Oatman, Stephanie R., PATEL, T, Wang, Xue, Reddy, Joseph S. , Allen, Mariet , Quicksall, Zachary , Tutor‐New, Frederick Q, Udine, Evan, Lin, Shu S., Carnwath, Troy , Deniz, Kaancan , Nguyen, Thuy T., Liu, C, Yamazaki, Yu , Martens, Yuka A. , Zhao, Na, Carrasquillo, Minerva M., Murray, Melissa E., Bu, GuoJun, Kanekiyo, Takahisa , Ertekin‐Taner, Nilüfer, Wang, Xue, Tutor‐New, Frederick Q, Udine, Evan , Nguyen, Thuy T. , Heckman, Michael G. , Carrasquillo, Minerva M. , Murray, Melissa E. , Bu, Guojun , Dickson, Dennis W. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_106658 Get It

Abstract Background More than 85% of Alzheimer's disease (AD) donor brains exhibit some degree of cerebral amyloid angiopathy (CAA), which is characterized predominantly by Aβ40 deposits in the brain vasculature and can cause blood brain barrier (BBB) leakage. CAA is associated with risk of infarcts, cerebral hemorrhages, and cognitive decline. Brain cell type‐specific mechanisms that influence CAA pathology, as well as related measures such as Aβ40 biochemical measures and tight junction proteins, an indicator of BBB integrity, are still elusive. Method We performed single‐nucleus RNA sequencing (snRNAseq) of temporal cortex tissue from 79 AD donors, with varying levels of CAA co‐pathology. Measurements of soluble, insoluble and membrane‐associated fractions of brain Aβ40 and tight junction protein (claudin‐5, occludin) levels were available for these donors. We correlated these measures with cell proportions. We also conducted differential gene expression and analyses for intercellular communications and regulatory networks. Result We identified 25 clusters and annotated them with major brain cell types. There were 3 oligodendrocyte, 7 excitatory and 7 inhibitory neuronal, 2 microglial, 2 astrocytic, and 1 each for endothelial, pericytic, fibroblast, and oligodendrocyte precursor cell clusters. We found that higher CAA and Aβ40 levels correlate with reduced neuronal and increased microglial, astrocytic and vascular cell proportions. Increased tight junction proteins correlate with increased inhibitory neuronal and reduced microglial, astrocytic and vascular cell proportions. Among all clusters, one microglial, both astrocytic and the pericytic clusters have greater number of genes significantly associated with CAA, Aβ40 and tight junction protein levels. Most significant genes have negative associations with CAA and membrane‐bound Aβ40 and positive with tight junction protein measures. Using these genes as input for intercellular communications analysis, we prioritized ligand‐target interactions from microglia or astrocytes to pericytes. Some of the prioritized targets are transcription factors in pericytes. Using regulon analysis, we identified genes downstream of these transcription factors that are also significantly associated with lower CAA and membrane‐bound Aβ40 and higher tight junction protein levels. Conclusion We revealed glia‐to‐pericytes intercellular interactions and pericytic gene regulatory networks that are potentially perturbed by CAA and BBB breakdown. Future directions include analyzing external snRNAseq datasets and performing functional validations.
Structural Variants Associated with Sporadic Alzheimer's Disease Pathologies and Segregates in Caribbean Hispanics and Non‐Hispanic White Families
Reyes‐Dumeyer, Dolly , Corvelo, André , Clarke, Wayne E. , Evani, Uday S. , Byrska‐Bishop, Marta S., Basile, Anna O. , Musunuri, Rajeeva O., Wang, H. , Faber, Kelley M., Goate, Alison M., Boeve, Brad F, Cruchaga, Carlos, Pericak‐Vance, Margaret, Haines, Jonathan L, Rosenberg, Roger N., Mejía, Diones Rivera , Medrano, Martin , Lantigua, Rafael , Bennett, David A. A., Wilson, Robert S., Foroud, Tatiana M., Lee, Wan‐Ping, Schellenberg, Gerald D., Dalgard, Clifton L., Mayeux, Richard, Zody, Michael C. , Vardarajan, Badri N., Gunasekaran, Tamil Iniyan , Byrska-Bishop, Marta , Runnels, Alexi , Musunuri, Rajeeva , Narzisi, Giuseppe , Goate, Alison , Cruchaga, Carlos , Pericak‐Vance, Margaret, Haines, Jonathan L, Tsuang, Debby W. , Sweet, Robert A. , Bennett, David A. , Wilson, Robert S. , Foroud, Tatiana M., Lee, Wan-Ping , Dalgard, Clifton L. , Mayeux, Richard , Vardarajan, Badri Narayan

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_107342 Get It

Abstract Background Alzheimer's disease (AD) exhibits significant genetic heterogeneity, with no single model fully explaining its inheritance pattern. Structural variants (SVs) may contribute to the missing heritability of AD, particularly in disease pathology and familial AD, which remain largely unexplored. Method Structural variants (SVs) were analyzed in unrelated 1,162 individuals from the ROSMAP study (687 cognitively normal (CN), 475 AD patients), as well as 197 Non‐Hispanic White (NHW) families (926 individuals, 58.5% with AD) and 214 Caribbean Hispanic (CH) families (1,340 individuals, 59.17% with AD). Large insertions and deletions were identified using Manta, Absinthe, and MELT from whole‐genome sequencing, supplemented by Sniffles2 and external SV call sets. This approach generated a unified VCF file containing 45,251 insertions and 76,566 deletions. After filtering for missingness rate and allele counts, a total of 9,290 insertions and 9,529 deletions were retained for analysis. Genome‐wide SV analyses were performed with AD‐related metrics in ROSMAP, adjusting for age, sex, and principal components, and validated in an independent ADSP replication cohort comprising 29,055 unrelated individuals (17,110 CN and 11,945 AD patients). Result We identified nine SVs (one insertion and eight deletions) segregating in AD families. An insertion near PDCD10 in NHW families reached genome‐wide significance ( p <5×10 ‐8 ) for AD risk in the replication cohort. Two deletions in KIF26B and SPHKAP were found in both CH and NHW families, while five appeared only in NHW and one in CH. All eight deletions showed genome‐wide significance for AD risk. SV GWAS on AD pathologies in ROSMAP revealed an insertion in INPP4B with the strongest association to global brain pathology (β=0.19; p = 2.32×10 ‐5 ), also linked to pathological AD, diffuse plaques, and Braak staging. A deletion near ADGRB1 (β=1.53; p = 5.05×10 ‐6 ) was associated with neuritic plaques, and another near ARMC2 (β=1.66; p = 2.17×10 ‐6 ) was linked to diffuse plaques. All three SVs associated with AD ( p <5×10 ‐6 ) in replication. Conclusion Our findings reveal numerous SVs segregating in familial AD across both CH and NHW families, as well as additional SVs linked to sporadic AD. Prioritizing these SVs based on their potential effects on gene function and expression will provide deeper insight into their contributions to both familial and sporadic AD.
Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study
Habermann, T. M., Gertz, Morie A, Porrata, Luis, Johnston, Patrick B. , Lin, Y., Buadi, Francis K. , Dingli, David , Wang, Yucai, Leung, Nelson, Kourelis, Taxiarchis , Witzig, TE, Warsame, Rahma , Cook, Joselle, Sher, Taimur , Gertz, Morie A. , Leung, Nelson , Wang, Yucai , Gertz, Morie A , Buadi, Francis K , Wang, Yucai , Leung, Nelson , Kourelis, Taxiarchis , Witzig, T.E. , Warsame, Rahma , Cook, Joselle M , Rosenthal, Allison C, Tun, Han W , Dispenzieri, Angela , Dingli, David , Nishimura, Yoshito , Cook, Joselle , Rosenthal, Allison , Tun, Han W. , Dispenzieri, Angela

Mayo Clinic

Blood Advances | December 24, 2025 | Volume: 10 | Issue: 5 | Pages: 1487-1496

10.1182/bloodadvances.2025018324 | PMID 41441992 Get It

Abstract Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders anatomically classified by distribution (unicentric CD [UCD], oligocentric CD [oligoCD], or multicentric CD [MCD]). Human herpes virus 8–negative MCD is called idiopathic MCD (iMCD), which includes clinical subtypes with varying phenotypes and responses: TAFRO (thrombocytopenia, anasarca, fever, renal dysfunction and/or reticulin fibrosis, and organomegaly), IPL (idiopathic plasmacytic lymphadenopathy), and not otherwise specified. OligoCD has recently emerged as an intermediate form between UCD and MCD, with unclear clinical behavior, and IPL has not been validated in a Western cohort. We retrospectively analyzed 217 patients with CD evaluated at our institution between January 2004 and August 2024. Survival probabilities were compared using log-rank tests. Overall, 57% had UCD, 20% had oligoCD, and 23% had iMCD. Patients with oligoCD and iMCD more frequently exhibited systemic symptoms than those with UCD. Patients with oligoCD and iMCD had significantly shorter event-free survival (EFS) of 8.9 and 2.3 years, respectively, than those with UCD (not reached; P&lt; .001 and P&lt; .02). Among iMCD subtypes, iMCD-IPL demonstrated a longer EFS than iMCD-TAFRO (P = .02), with no deaths during the follow-up periods. The results validate oligoCD and iMCD-IPL as new subtypes in this Western cohort. The survival outcome in oligoCD was intermediate between UCD and iMCD, with only a subset of patients with oligoCD requiring systemic therapy. iMCD-IPL had a favorable survival outcome in this US cohort, similar to what has been reported in non-Western countries. Tailoring treatment strategies to disease subtypes and vigilant monitoring of oligoCD for progression may improve survival outcomes in CD.
X Chromosome Genetic Risk Across Sex, APOE*4, and Pleiotropic Traits Reveals Novel Alzheimer's Disease Mechanisms and Risk Genes
Cook, Noah, Yang, Chenyu, Wang, Ting‐Chen, Sherva, Richard, Zhang, Rui, Panizzon, Matthew S., Hauger, R. L., Gaziano, J. Michael, Koran, Mary Ellen I. , Mormino, Beth C., Logue, Mark W., Greicius, Michael D. , Program, the VA Million Veteran, FinnGen, Cook, Noah, Yang, Chenyu , Reid, Danielle Marie , Wang, Ting‐Chen , Le Guen, Yann , Cody, Karly A , Sherva, Richard , Zhang, Rui, Merritt, Victoria C. , Panizzon, Matthew S. , Gaziano, J. Michael , Dumitrescu, Logan , Archer, Derek B. , Hohman, Timothy J. , Logue, Mark W. , Napolioni, Valerio , Belloy, Michaël E.

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_098765 Get It

Abstract Background Our group recently performed the largest‐to‐date X‐chromosome wide association study (XWAS) of Alzheimer's disease (AD). Here, we expand on this with additional samples, novel sex‐ and APOE *4‐stratified analyses, and evaluate escape from random X chromosome inactivation (eXCI) to better capture female‐biased risk genes. We then integrate these results with XWASs of various AD‐relevant traits to elucidate shared genetic signals and ultimately uncover novel AD risk genes and mechanisms. Method The AD XWAS design is shown in Figure 1A and includes random X chromosome inactivation (rXCI) and eXCI models. We further assessed suggestive AD signals ( p <1x10 ‐3 ) for pleiotropy using genetic colocalization with 2852 AD‐relevant traits (Figure 2A). Loci exhibiting X chromosome‐wide significance ( p <1x10 ‐5 ) or apparent trait colocalization underwent quantitative trait locus (QTL) colocalization analyses across 62 tissues and cell types to functionally prioritize AD risk genes. Result Full sample analyses reproduced Belloy et al. 2024 findings and identified 3 additional loci, including a male‐specific signal near GLUD2 that impacts glutamate/glutamine metabolism (Figure 1B). APOE *4‐stratified analyses revealed 9 additional loci, including 3 eXCI hits in APOE *4 carriers (Figure 1C‐D). Pleiotropy colocalization identified 38 loci, most being novel and many driven by eXCI and/or female‐specific AD XWAS, including MOSPD2, PNMA3 and GABRE loci that showed extensive colocalization with brain imaging traits (Figure 2B). The most significant XWAS locus, SLC9A7 , colocalized with total testosterone, HDL‐C, and various brain imaging traits. Only the NLGN4X locus colocalized with amyloid positivity, linking its proposed role in synaptic dysfunction to amyloid pathology. The locus at KDM6A , previously implicated as an AD resilience gene, colocalized with a functional MRI (fMRI) phenotype. QTL colocalization analyses confirmed gene prioritizations in Belloy et al. 2024, and additionally provided support for PNMA3 , an antigen highly expressed in the brain, and 3 APOE ‐stratified loci, including ACLS4 , which impacts lipid metabolism. Conclusion This study provides novel insights into biological mechanisms that contribute to X‐linked genetic risk for AD in an APOE *4 and sex‐specific manner, identifying various novel risk loci. Notably, 29 female‐biased risk loci were uncovered, which may shed light on sex disparities in AD. Overall, our findings will aid in elucidating AD pathways and drug targets relevant to personalized medicine.
Microglia‐dependent protective and risk signatures driven by Alzheimer's disease genetic factors
İş, Özkan , Tan, Jianna, Bergman, Jeremiah, Wang, Xue, Tutor‐New, Frederick Q, Min, Yuhao , Quicksall, Zachary , Atik, Merve, Reddy, Joseph S. , Gao, Junli, Tsai, Wei, Sotelo, Katie D., Nguyen, Thuy T. , Kanekiyo, Takahisa , Allen, Mariet , Ertekin‐Taner, Nilüfer, Tutor‐New, Frederick Q, Atık, Merve, Sotelo, Katie D., Dickson, Dennis W. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_098044 Get It

Abstract Background Alzheimer's disease (AD) affects all brain cells and has complex genomic and immunological alterations. Previous research discovered missense AD risk or protective variants in microglial genes ABI3 and PLCG2, respectively. Expression levels of these genes are altered in AD and can influence microglial function. This study aims to uncover protective, and risk microglial molecular signatures associated with these variants to determine their role in microglial subtypes and states in AD by single cell expression and functional studies. Method We generated microglia‐enriched snRNAseq data from donors harboring either AD protective PLCG2 or AD risk ABI3 missense mutations, or neither mutation. After standard snRNAseq QC, we performed differential expressed gene (DEG) analysis of all microglial cells between variant carriers and non‐carriers using MAST. We defined protective signature as genes that are both down in ABI3 and up in PLCG2 mutation‐carriers. In contrast, risk signature genes are up in ABI3 and down in PLCG2 mutation‐carriers. We investigated the conservation of protective and risk signatures across multiple datasets, including scRNAseq data from iPSC‐derived microglia cells carrying PLCG2 protective variant, snRNAseq data from AD‐resilient donors, and data from AD and other diagnostic groups across multiple brain regions sourced from external datasets. Result We obtained snRNAseq profiles of 35,000 microglia from AD variant carriers. Our DEG analysis among all microglia cells provided 227 microglial protective and 293 risk signature genes defined by these variants. Using integrated analysis of multiple internal and external datasets, we further narrowed down these signatures. We determined that these high‐confidence protective signature genes are downregulated in early AD, upregulated in late AD brains and positively‐correlated with protective variant load in in vitro models. In contrast, risk signature genes are upregulated in early AD, downregulated in late AD and resilient donors. Risk signature expression is decreased with protective PLCG2 variant load, and altered with Aβ treatment in in vitro models. Conclusion Our study uncovers microglia specific protective and risk signatures associated with AD using sn/scRNAseq datasets from multiple sources and models. These findings nominate novel immune targets and pathways with implications for microglial function in health and disease, and ultimately therapeutic potential.
Investigating the role of the exposome on neuropathology and biochemical phenotypes in Alzheimer’s disease
Garofalo, Gabriela , Reddy, Joseph S. , HECKMAN, M, Oatman, Stephanie R., Wang, Xue, Nguyen, Thuy T. , Murray, Melissa E., Kanekiyo, Takahisa , Carrasquillo, Minerva M., Allen, Mariet , Ertekin‐Taner, Nilüfer, Heckman, Michael G. , Murray, Melissa E. , Dickson, Dennis W. , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S7 | Pages: No page available

10.1002/alz70861_108874 Get It

Abstract Background Individual environmental exposures, the exposome, can play an influential role in the development and progression of neurodegenerative diseases such as AD. The protein components of the main AD neuropathologies, amyloid (Aβ) plaques and tau neurofibrillary tangles (NFTs), can be measured using immunohistochemical and biochemical approaches. The main genetic risk factor for AD is the APOE e4 allele. APOE levels can also be measured in the brain. We hypothesize that social determinants of health, specifically alcohol and tobacco consumption, and the area deprivation index (ADI), could play a considerable role in severity of neuropathology and brain biochemical phenotypes of AD. Method We evaluated 478 neuropathologically characterized AD donors, from the Mayo Clinic Brain Bank. 469 samples had available biochemical measures (APOE, Aβ40, Aβ42, tau, and phospho‐tau (Thr231)), collected across three isolated fractions (soluble (TBS), membrane‐bound (TX), and insoluble (FA)) of the superior temporal gyrus. Exposome variables were extracted from the available records. ADI from the Neighborhood Atlas® version from the year 2015 was obtained from de‐identified addresses. ADI, smoking and alcohol were available for 263 of these donors and were examined for association with biochemical measures using linear regression adjusting for age at death and sex. Result Higher ADI levels representing neighborhoods with increased deprivation, were nominally associated (β=0.006, p =0.01) with soluble levels of APOE. Alcohol consumption was associated with lower levels of membrane bound APOE (β=‐0.23, p =0.04). Analysis with neuropathological variables including CAA ( N =454), Braak ( N =454), Thal ( N =454), Hippocampal sclerosis ( N =453), Lewy bodies ( N =455) will also be performed. Conclusion Different components of the social exposome may impact levels of core AD proteins. Additional analyses in expanded cohorts to further explore the associations with neuropathology are ongoing. We expect that understanding how the social exposome impacts specific aspects of neurodegenerative diseases will provide key insights into underlying, potentially modifiable, mechanisms of disease.
Microglia‐dependent protective and risk signatures driven by Alzheimer's disease genetic factors
İş, Özkan , Tan, Jianna, Bergman, Jeremiah, Wang, Xue, Tutor‐New, Frederick Q, Min, Yuhao , Quicksall, Zachary , Atik, Merve, Reddy, Joseph S. , Gao, Junli, Tsai, Wei, Sotelo, Katie D., Nguyen, Thuy T. , Kanekiyo, Takahisa , Allen, Mariet , Ertekin‐Taner, Nilüfer, Tutor‐New, Frederick Q, Atık, Merve, Sotelo, Katie D., Dickson, Dennis W. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_110127 Get It

Abstract Background Alzheimer's disease (AD) affects all brain cells and has complex genomic and immunological alterations. Previous research discovered missense AD risk or protective variants in microglial genes ABI3 and PLCG2 , respectively. Expression levels of these genes are altered in AD and can influence microglial function. This study aims to uncover protective, and risk microglial molecular signatures associated with these variants to determine their role in microglial subtypes and states in AD by single cell expression and functional studies. Method We generated microglia‐enriched snRNAseq data from donors harboring either AD protective PLCG2 or AD risk ABI3 missense mutations, or neither mutation. After standard snRNAseq QC, we performed differential expressed gene (DEG) analysis of all microglial cells between variant carriers and non‐carriers using MAST. We defined protective signature as genes that are both down in ABI3 and up in PLCG2 mutation‐carriers. In contrast, risk signature genes are up in ABI3 and down in PLCG2 mutation‐carriers. We investigated the conservation of protective and risk signatures across multiple datasets, including scRNAseq data from iPSC‐derived microglia cells carrying PLCG2 protective variant, snRNAseq data from AD‐resilient donors, and data from AD and other diagnostic groups across multiple brain regions sourced from external datasets. Result We obtained snRNAseq profiles of 35,000 microglia from AD variant carriers. Our DEG analysis among all microglia cells provided 227 microglial protective and 293 risk signature genes defined by these variants. Using integrated analysis of multiple internal and external datasets, we further narrowed down these signatures. We determined that these high‐confidence protective signature genes are downregulated in early AD, upregulated in late AD brains and positively‐correlated with protective variant load in in vitro models. In contrast, risk signature genes are upregulated in early AD, downregulated in late AD and resilient donors. Risk signature expression is decreased with protective PLCG2 variant load, and altered with Aβ treatment in in vitro models. Conclusion Our study uncovers microglia specific protective and risk signatures associated with AD using sn/scRNAseq datasets from multiple sources and models. These findings nominate novel immune targets and pathways with implications for microglial function in health and disease, and ultimately therapeutic potential.
Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab
Joseph‐Mathurin, Nelly, Chen, Charles D., Flores, Shaney, Scott, Jalen , Anand, Sanjana, Franklin, Erin E., Lu, Ruijin , Gordon, Brian A., Jack, C. R., Cruchaga, Carlos C, Hassenstab, Jason J., Ibanez, Laura, Li, Yan, Wang, Guoqiao, Renton, Alan E., Xiong, Chengjie, Atri, A., Snider, B. Joy, Clifford, David B., Bateman, Randall J., Wang, Q., Perrin, Richard J., Benzinger, Tammie L.S., Jack, Clifford R. , Jack, Clifford R , Joseph‐Mathurin, Nelly , Hobbs, Diana A. , Jiang, Meng, Flores, Shaney , Franklin, Erin , Gordon, Brian A. , Cruchaga, Carlos , Ibanez, Laura , Wang, Guoqiao , Renton, Alan , Xiong, Chengjie , Snider, B. Joy, Llibre‐Guerra, Jorge J. , Clifford, David B. , McDade, Eric , Bateman, Randall J. , Perrin, Richard J. , Benzinger, Tammie L.S.

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_110062 Get It

Abstract Background Amyloid related imaging abnormality edema (ARIA‐E) occurs in about 19% of individuals with autosomal dominant Alzheimer disease (ADAD) treated with an anti‐amyloid‐b monoclonal antibody (Salloway et al., 2021). In a previously reported case, ARIA‐E appeared to colocalize with decreases in PiB‐PET uptake (Joseph‐Mathurin, Llibre‐Guerra, et al, 2022), suggesting an association between amyloid‐b (Aβ) removal and ARIA‐E. Here, we compare longitudinal neuroimaging and corresponding neuropathology in an ADAD individual treated with gantenerumab, who experienced multiple ARIA‐E episodes as sulcal effusions that resolved by the end of the four‐year trial. Methods PiB‐PET and MRI were collected pre‐ and post‐randomization (2 and 4 years). The participant consented to brain donation, which was received a year after trial completion. Four tissue samples were taken from the location of the ARIA‐E in the parieto‐occipital left hemibrain as identified by MRI (one block contained the sulcus affected by ARIA‐E; the rest of the coronal section was captured in the remaining three blocks). Area fractions (AFs) of Aβ (10D5 immunohistochemistry (IHC)), tauopathy (PHF1), microglia (Iba1), and astrocytes (GFAP) in one sulcal region of interest (ROI) from each block and PiB‐PET SUVRs of corresponding ROIs were extracted ( n = 4, Figure 1). Additionally, we included PiB‐PET SUVRs corresponding to ARIA‐E findings observed in the right hemisphere at baseline, two‐year, and four‐year visits ( n = 6). Results Overall PiB‐PET uptake increased during the first two years (before ARIA‐E) and decreased during the last two years (including ARIA‐E episodes) (0.03±0.05 vs. ‐0.04±0.04 SUVR/year, p ‐value=0.01, Figure 2). The decrease seemed more pronounced in ARIA‐E ROIs versus normal‐appearing sulcus ROIs (‐0.05±0.04 vs. ‐0.02±0.03 SUVR/year). Lower PiB uptake at last visit appeared associated with lower Aβ AF (estimates=0.03±0.01, p ‐value=0.07). The ARIA‐E ROI had an Aβ AF of 0.009 while normal‐appearing sulcus ROIs had a mean of 0.02+0.003 (Figure 3). AFs for tauopathy, microglia, and astrocytes were within the range of those of normal‐appearing sulcus ROIs, suggesting an Aβ‐specific effect, although unexamined markers may play a role. Conclusions Our preliminary findings indicated that ARIA‐E is associated with longitudinal PiB‐PET decrease and Aβ AF, supporting the link between ARIA‐E, changes in PiB‐PET, and local Aβ removal observed at autopsy. Funding : K01AG080123; U01AG042791; R01AG046179; R01AG053267
Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N. , Carrillo, Maria, Casaletto, Kaitlin B, Chang, C. -C., Chang, Hsin‐I., Chao, Yishu , Chetelat, Gaël, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hansson, Oskar H., Huang, Q., Huang, Shu‐Hua , Ishii, Kenji, Jagust, William J., Kato, Takashi , Koeppe, R. A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J. , Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C. , Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis G., Rowe, C. C., Schott, Jonathan M, Schwartz, Daniel L. , Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz, Smith, Ruben, Sokołowski, Andrzej , Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, David E. , Flier, Wiesje M. van der, Vemuri, Prashanthi, Villain, Nicolas , Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Wang, Wei‐en , Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Casaletto, Kaitlin B. , Cash, David M. , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Brad C., Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kazunari , Jagust, William J. , Kramer, Joel H. , Landau, Susan, Landeau, Brigitte , Masters, Colin L. , Mézenge, Florence, Nakamura, Akinori , O’Bryant, Sid E. , Peretti, Débora Elisa , Quenon, Lisa , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Sokolowski, Andrzej, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_110011 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen’s kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure‐1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure‐1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure‐2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure‐2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.